Literature DB >> 22911901

Association of genetic variations in DTNBP1 with cognitive function in schizophrenia patients and healthy subjects.

Ji Hyun Baek1, Ji Sun Kim, Seunghyong Ryu, Sohee Oh, Jihae Noh, Woo Kyeong Lee, Taesung Park, Yu-Sang Lee, Dongsoo Lee, Jun Soo Kwon, Kyung Sue Hong.   

Abstract

The dystrobrevin-binding protein 1 gene (DTNBP1) has been regarded as a susceptibility gene for schizophrenia. Recent studies have investigated its role on cognitive function that is frequently impaired in schizophrenia patients, and generated inconsistent results. The present study was performed to elucidate effects of genetic variations in DTNBP1 on various cognitive domains in both schizophrenia patients and healthy subjects. Comprehensive neuropsychological tests were administered to 122 clinically stable schizophrenia patients and 119 healthy subjects. Based on positive findings reported in previous association studies, six SNPs were selected and genotyped. Compared to healthy subjects, schizophrenia patients showed expected lower performance for all of the cognitive domains. After adjusting for age, gender, and educational level, four SNPs showed a nominally significant association with cognitive domains. The association of rs760761 and rs1018381 with the attention and vigilance domain remained significant after applying the correction for multiple testing (P < 0.001). Similar association patterns were observed both, in patients and healthy subjects. The observed results suggest the involvement of DTNBP1 not only in the development of attention deficit of schizophrenia, but also in the inter-individual variability of this cognitive domain within the normal functional range. 2012 Wiley Periodicals, Inc

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22911901     DOI: 10.1002/ajmg.b.32091

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  9 in total

1.  Exome Sequence Data From Multigenerational Families Implicate AMPA Receptor Trafficking in Neurocognitive Impairment and Schizophrenia Risk.

Authors:  Mark Z Kos; Melanie A Carless; Juan Peralta; August Blackburn; Marcio Almeida; David Roalf; Michael F Pogue-Geile; Konasale Prasad; Ruben C Gur; Vishwajit Nimgaonkar; Joanne E Curran; Ravi Duggirala; David C Glahn; John Blangero; Raquel E Gur; Laura Almasy
Journal:  Schizophr Bull       Date:  2015-09-24       Impact factor: 9.306

2.  COMT, BDNF, and DTNBP1 polymorphisms and cognitive functions in patients with brain tumors.

Authors:  Denise D Correa; Jaya Satagopan; Kenneth Cheung; Arshi K Arora; Maria Kryza-Lacombe; Youming Xu; Sasan Karimi; John Lyo; Lisa M DeAngelis; Irene Orlow
Journal:  Neuro Oncol       Date:  2016-04-18       Impact factor: 12.300

3.  Loss of dysbindin-1 affects GABAergic transmission in the PFC.

Authors:  H Trantham-Davidson; A Lavin
Journal:  Psychopharmacology (Berl)       Date:  2019-06-14       Impact factor: 4.530

4.  Dysregulation of Specialized Delay/Interference-Dependent Working Memory Following Loss of Dysbindin-1A in Schizophrenia-Related Phenotypes.

Authors:  Emilie I Petit; Zuzanna Michalak; Rachel Cox; Colm M P O'Tuathaigh; Niamh Clarke; Orna Tighe; Konrad Talbot; Derek Blake; Josephine Joel; Alexander Shaw; Steven A Sheardown; Alastair D Morrison; Stephen Wilson; Ellen M Shapland; David C Henshall; James N Kew; Brian P Kirby; John L Waddington
Journal:  Neuropsychopharmacology       Date:  2016-12-16       Impact factor: 7.853

Review 5.  Dysbindin-1 Involvement in the Etiology of Schizophrenia.

Authors:  Haitao Wang; Jiangping Xu; Philip Lazarovici; Wenhua Zheng
Journal:  Int J Mol Sci       Date:  2017-09-22       Impact factor: 5.923

6.  Consensus on potential biomarkers developed for use in clinical tests for schizophrenia.

Authors:  Ping Lin; Junyu Sun; Xiaoyan Lou; Dan Li; Yun Shi; Zhenhua Li; Peijun Ma; Ping Li; Shuzi Chen; Weifeng Jin; Shuai Liu; Qing Chen; Qiong Gao; Lili Zhu; Jie Xu; Mengyuan Zhu; Mengxia Wang; Kangyi Liang; Ling Zhao; Huabin Xu; Ke Dong; Qingtian Li; Xunjia Cheng; Jinghong Chen; Xiaokui Guo
Journal:  Gen Psychiatr       Date:  2022-02-23

7.  Association of the Hermansky-Pudlak syndrome type 4 (HPS4) gene variants with cognitive function in patients with schizophrenia and healthy subjects.

Authors:  Go Kuratomi; Atsushi Saito; Yuji Ozeki; Takashi Watanabe; Kumiko Fujii; Kazutaka Shimoda; Toshihiko Inukai; Harunobu Mori; Kenichi Ohmori; Kazufumi Akiyama
Journal:  BMC Psychiatry       Date:  2013-10-30       Impact factor: 3.630

8.  Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantine.

Authors:  Maju Mathew Koola
Journal:  Schizophr Res Cogn       Date:  2016-06

Review 9.  Developmental Genes and Regulatory Proteins, Domains of Cognitive Impairment in Schizophrenia Spectrum Psychosis and Implications for Antipsychotic Drug Discovery: The Example of Dysbindin-1 Isoforms and Beyond.

Authors:  John L Waddington; Xuechu Zhen; Colm M P O'Tuathaigh
Journal:  Front Pharmacol       Date:  2020-01-29       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.